Mechanisms Affecting Gut of Preterm Infants (MAGPIE)

  • Research type

    Research Study

  • Full title

    Mechanisms Affecting the Gut of Preterm Infants in Enteral feeding trials(MAGPIE)

  • IRAS ID

    180222

  • Contact name

    Nicholas D Embleton

  • Contact email

    nicholas.embleton@ncl.ac.uk

  • Sponsor organisation

    Newcastle Hospitals NHS Foundation Trust

  • Duration of Study in the UK

    3 years, 11 months, 31 days

  • Research summary

    Premature birth is associated with high rates of death, and worse outcomes in survivors. Over the last 20 years, respiratory support has improved meaning more babies now survive. Now, the most common causes of serious illness after the first week are due to gut complications or infections. Necrotising enterocolitis (NEC) is a serious gut disease occurring in premature babies. NEC affects 1 in 10 babies born more than 8 weeks early; 1 in 3 of them require major surgery or die. Infections affect 1 in 5 premature babies, may cause death, and doubles the risk of long term problems such as cerebral palsy. Our group is already undertaking an NIHR funded study (ELFIN) to examine whether the way we feed premature babies affects rates of infection, NEC and brain outcomes: ELFIN - Enteral Lactoferrin in Neonates. That study will tell us whether lactoferrin is a useful treatement for all babies, but it does not tell us how the treatment works. The MAGPIE study (Mechanisms Affecting the Gut of Preterm Infants in Enteral Feeding Studies) will be run alongside ELFIN in a sub-set of babies (around 480 out of the total 2200 babies anticipated to join ELFIN). Babies who have joined ELFIN will be eligible to join the MAGPIE study if they are cared for in a participating hospital. The MAGPIE study simply involves collecting a daily specimen of stool and urine from the baby during hospital stay, and analysing any residual gut tissue if an operation was needed. The samples will be analysed to see if the pattern of gut bacteria affects gut function and will tell us how lactoferrin is working. The samples collected are all non-invasive and pose no additional risk to the baby. They will not affect the conduct of the main ELFIN study or usual medical treatments.

  • REC name

    East Midlands - Nottingham 2 Research Ethics Committee

  • REC reference

    16/EM/0042

  • Date of REC Opinion

    29 Feb 2016

  • REC opinion

    Favourable Opinion